View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMedesis Pharma 배당 및 자사주 매입배당 기준 점검 0/6Medesis Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .공시 • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues FranceNew Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).공시 • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 76D 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 76D 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Medesis Pharma 배당 수익률 vs 시장76D의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (76D)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.5%업계 평균 (Biotechs)2.2%분석가 예측 (76D) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 76D 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 76D 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 76D 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 76D 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/05/15 15:45종가2025/03/11 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Medesis Pharma S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 15Medesis Pharma S.A.(ENXTPA:ALMDP) dropped from Next Biotech IndexMedesis Pharma S.A. has been dropped from the Next Biotech Index .
공시 • Aug 20Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024Medesis Pharma S.A., Annual General Meeting, Sep 25, 2024. Location: oree des mas les cypres, avenue du golf, baillargues France
New Risk • Jul 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 13% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-€4.5m). Revenue is less than US$1m (€300k revenue, or US$327k). Market cap is less than US$10m (€4.46m market cap, or US$4.86m). Minor Risk Shareholders have been diluted in the past year (13% increase in shares outstanding).
New Risk • May 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-€2.6m). Revenue is less than US$1m (€429k revenue, or US$463k). Market cap is less than US$10m (€5.96m market cap, or US$6.43m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
공시 • Apr 06Medesis Pharma Publishes an Information Note on the Three Future Drugs in Development for the Protection of Large Populations Contaminated After A Civil or Military Nuclear AccidentMedesis Pharma published an information note on the three future drugs in development for the protection of large populations contaminated after a civil or military nuclear accident. Three drugs are specifically intended for the treatment of large populations contaminated or irradiated after a civil or military nuclear accident. To date, there is no suitable treatment for a serious nuclear accident. The three products are at the heart of the issues with the tragic international situation in Ukraine, raising the possibility of nuclear war. They are also topical with the recent decisions to maintain the development of nuclear power plants. Medesis Pharma's three drug candidates were developed in collaboration with the French Atomic Energy Commission (LRT-CEA), which carried out all the studies on animals contaminated by radionuclides, and with the Armed Forces Biomedical Research Institute (IRBA) for studies on irradiated animals. Each of these products is protected by an international patent registered or in the process of being registered in most nuclear countries in the world. The therapeutic activity has been demonstrated, and a complementary program is necessary with pharmaceutical development for industrial production and a tolerance study on healthy volunteers to demonstrate safety before introducing the products into State emergency stocks. Funding requests for these 3 programs have been submitted by Medesis Pharma to the French Defense Innovation Agency. NU01: NanoCaDTPA: Plutonium decorporation: For more than 40 years, CaDTPA has been used by repeated slow IV infusion over several weeks. However, this treatment carried out in a medical environment is suitable for a few contaminated people (workers in Nuclear Power Plants), but impossible to implement when several hundred thousand people are contaminated. NanoCaDTPA (formulation of CaDTPA in the Aonys microemulsion) makes it possible to obtain the same efficiency of extraction of Plutonium, but with simple administration in the mouth, from a bottle stored at room temperature. NU02: NanoPB (Prussian Blue): Cesium decorporation: Prussian Blue has been used for many years for the extraction of Cesium. It is administered in large capsules of 500 mg, 18 capsules per day for 2 to 3 months. Impossible to dissolve, it is almost impossible to give to children and adolescents and is accompanied by obstinate constipation resulting in irradiation of the small pelvis. However, Cesium is fixed preferentially in the muscles and in particular in the heart muscle causing abnormalities and cardiac pathologies in children and adolescents. The NanoPB consists of Prussian Blue nanoparticles synthesized and stabilized in the Aonys microemulsion. It allows to obtain a decorporation of cesium 3 times faster with 100 times less Prussian Blue. It is drinkable and suitable for administration at any age, including infants and children. NP02: NanoManganese: The active ingredient is manganese sulphate in the Aonys microemulsion. This product prevents and treats the storm of inflammatory cytokines triggered by irradiation that causes major respiratory and digestive inflammation responsible for death. Efficacy is observed if treatment is started within hours of irradiation. It is administered by mouth and stored in bottles at room temperature. This product is currently in a Phase II clinical study in Brazil to treat severe forms of COVID-19 which are also linked to an inflammatory cytokine storm. Product development Plan: For each of the two decorporation products of Plutonium and Cesium: Pharmaceutical CMC development with preparation for industrial production, Tolerance study on 50 healthy volunteers treated for one month. For the radiation protection product already in clinical development: Industrial development, Tolerance study on 50 healthy volunteers for one month. Deadlines for product registration and industrial manufacturing: 18 months for the two decorporation products; 12 months for the radiation protection product. In practice, these deadlines can be shortened or extended depending on whether or not the Medicines Agency and the public authorities consider it urgent.